Acquisition - November 24, 2021
Novo Nordisk to acquire Dicerna Pharmaceuticals
Novo Nordisk has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna) for a total equity value of approximately USD 3.3 billion. The acquisition of Dicerna’s ribonucleic acid interference (RNAi) platform is a strategic addition to Novo Nordisk’s existing research technology platforms and supports the strategy of using a broad range of technology platforms […]
Acquisition - November 11, 2021
Organon acquires Forendo Pharma
The global pharmaceutical company Organon is acquiring its portfolio company Forendo Pharma. Forendo Pharma’s shareholders will receive an initial payment of USD 75 million and are entitled to additional future payments totaling USD 870 million upon the achievement of certain development, registration and commercial milestones pertaining to Forendo Pharma’s drug candidates. The total purchase price, […]
Acquisition - November 1, 2021
AstraZeneca to transfer global rights for Eklira and Duaklir
AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorzain the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma. Both medicines are delivered via the Genuair device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD). The agreement will ensure continued patient access to these established […]
Acquisition - October 26, 2021
Agnafit Bidco extends the acceptance period for the Sobi offer
Following receipt of all regulatory approvals, Agnafit Bidco extends the acceptance period for the public offer to the shareholders of Sobi and announces its intention not to increase the price of SEK 235 per share in the Offer. On 2 September 2021, Advent International Corporation1 and Aurora Investment Pte Ltd2, an affiliate of GIC Pte […]
Acquisition - October 22, 2021
Lundbeck acquires exclusive rights to APB-A1 from AprilBio
Lundbeck has entered into a definitive agreement with AprilBio, a biopharmaceutical company based in South Korea. Under the agreement between the two companies, Lundbeck receives exclusive, worldwide rights to research, develop and commercialize APB-A1, a novel and well-differentiated anti-CD40 ligand (CD40L) antibody-like drug candidate, ready for phase I testing around the beginning of 2022. This […]
Acquisition - October 18, 2021
Flerie Invest leads acquisition of Cobra Biologics Matfors AB
Flerie Invest led a syndicate of investors in the 52 million USD acquisition of Charles River Laboratories Inc’s DNA and protein manufacturing subsidiary Cobra Biologics Matfors AB, including its 7,000 square-meter facility. The new entity will be called NorthX Biologics AB. “This acquisition is a major investment for us and fits well with Flerie’s strategy […]
